EMBRACA
The safety of TALZENNA as a single agent was evaluated in gBRCAm patients with HER2-negative locally advanced or metastatic breast cancer who had previously received no more than 3 lines of chemotherapy for the treatment of locally advanced/metastatic disease [see Clinical Studies (14.1)]. EMBRACA was a randomized, open-label, multi-center study in which 412 patients received either TALZENNA 1 mg once daily (N=286) or a chemotherapy agent (capecitabine, eribulin, gemcitabine, or vinorelbine) of the healthcare provider's choice (N=126) until disease progression or unacceptable toxicity. The median duration of study treatment was 6.1 months in patients who received TALZENNA and 3.9 months in patients who received chemotherapy.
Serious adverse reactions of TALZENNA occurred in 32% of patients. Serious adverse reactions reported in >2% of patients included anemia (6%) and pyrexia (2%). Fatal adverse reactions occurred in 1% of patients, including cerebral hemorrhage, liver disorder, veno-occlusive liver disease, and worsening neurological symptoms (1 patient each).
Permanent discontinuation due to adverse reactions occurred in 5% of TALZENNA patients. Dosing interruptions due to an adverse reaction of any grade occurred in 65% of patients receiving TALZENNA; dose reductions due to any cause occurred in 53% of TALZENNA patients.
The most common (≥20%) adverse reactions, including laboratory abnormalities, were hemoglobin decreased, neutrophils decreased, lymphocytes decreased, platelets decreased, fatigue, glucose increased, aspartate aminotransferase increased, alkaline phosphatase increased, alanine aminotransferase increased, calcium decreased, nausea, headache, vomiting, alopecia, diarrhea, and decreased appetite.
Table 5 and Table 6 summarize the most common adverse reactions and laboratory abnormalities, respectively, in patients treated with TALZENNA or chemotherapy in the EMBRACA study.
Table 5. Adverse Reactions* (≥20%) in Patients Receiving TALZENNA in EMBRACA Adverse Reactions | TALZENNA N=286 (%) | Chemotherapy N=126 (%) |
---|
Grades 1–4 | Grade 3 | Grade 4 | Grades 1–4 | Grade 3 | Grade 4 |
---|
Abbreviation: N=number of patients. |
|
General disorders and administration site conditions |
Fatigue† | 62 | 3 | 0 | 50 | 5 | 0 |
Gastrointestinal disorders |
Nausea | 49 | 0.3 | 0 | 47 | 2 | 0 |
Vomiting | 25 | 2 | 0 | 23 | 2 | 0 |
Diarrhea | 22 | 1 | 0 | 26 | 6 | 0 |
Nervous system disorders |
Headache | 33 | 2 | 0 | 22 | 1 | 0 |
Skin and subcutaneous tissue disorders |
Alopecia | 25 | 0 | 0 | 28 | 0 | 0 |
Metabolism and nutrition disorders |
Decreased appetite | 21 | 0.3 | 0 | 22 | 1 | 0 |
Clinically relevant adverse reactions in <20% of patients who received TALZENNA included abdominal pain (19%), dizziness (17%), dysgeusia (10%), dyspepsia (10%), stomatitis (8%), and febrile neutropenia (0.3%).
Table 6. Select Laboratory Abnormalities (≥25%) of Patients in EMBRACA | TALZENNA N*=286 (%) | Chemotherapy N*=126 (%) |
---|
Parameter | Grades 1–4 | Grade 3 | Grade 4 | Grades 1–4 | Grade 3 | Grade 4 |
---|
Abbreviation: N=number of patients. |
|
Hemoglobin decreased | 90 | 39 | 0 | 77 | 6 | 0 |
Neutrophils decreased | 68 | 17 | 3 | 70 | 21 | 17 |
Lymphocytes decreased | 76 | 17 | 0.7 | 53 | 8 | 0.8 |
Platelets decreased | 55 | 11 | 4 | 29 | 2 | 0 |
Glucose increased† | 54 | 2 | 0 | 51 | 2 | 0 |
Aspartate aminotransferase Increased | 37 | 2 | 0 | 48 | 3 | 0 |
Alkaline phosphatase increased | 36 | 2 | 0 | 34 | 2 | 0 |
Alanine aminotransferase increased | 33 | 1 | 0 | 37 | 2 | 0 |
Calcium decreased | 28 | 1 | 0 | 16 | 0 | 0 |
HRR Gene-mutated mCRPC
The safety of TALZENNA in combination with enzalutamide was evaluated in patients with HRR gene-mutated mCRPC enrolled in TALAPRO-2 [see Clinical Studies (14.2)]. Patients were randomized to receive either TALZENNA 0.5 mg in combination with enzalutamide 160 mg once daily (n=197), or placebo in enzalutamide 160 mg once daily (n=199) until disease progression or unacceptable toxicity. Among patients receiving TALZENNA, 86% were exposed for 6 months or longer, 60% were exposed for greater than one year, and 18% were exposed for greater than two years.
Serious adverse reactions of TALZENNA in combination with enzalutamide occurred in 30% of patients. Serious adverse reactions reported in >2% of patients included anemia (9%) and fracture (3%). Fatal adverse reactions occurred in 1.5% of patients, including pneumonia, COVID infection, and sepsis (1 patient each).
Permanent discontinuation of TALZENNA due to adverse reactions occurred in 10% of patients treated in the TALZENNA with enzalutamide arm. The most common adverse reactions which resulted in permanent discontinuation of TALZENNA were anemia (4%), fatigue, bone fracture, ischemic heart disease, and spinal cord compression (1% each).
Dosage interruption of TALZENNA due to adverse reactions occurred in 58% of patients treated in the TALZENNA with enzalutamide arm. The most common adverse reactions which resulted in dose interruption of TALZENNA were anemia (42%), neutropenia (15%), and platelet count decreased (9%) and fatigue (5%).
Dose reduction of TALZENNA due to adverse reactions occurred in 52% of patients treated in the TALZENNA with enzalutamide arm. The most common adverse reactions which resulted in dose reduction of TALZENNA were anemia (43%), neutrophil count decreased (15%), platelet count decreased (6%), and fatigue (4%).
The most common adverse reactions (≥10%), including laboratory abnormalities, in patients who received TALZENNA with enzalutamide were hemoglobin decreased, neutrophils decreased, lymphocytes decreased, fatigue, platelets decreased, calcium decreased, nausea, decreased appetite, sodium decreased, phosphate decreased, fractures, magnesium decreased, dizziness, bilirubin increased, potassium decreased, and dysgeusia.
Table 7 and Table 8 summarize the most common adverse reactions and laboratory abnormalities, respectively, in the TALAPRO-2 study.
Table 7. Adverse Reactions* (≥10%) in Patients Receiving TALZENNA [with a Difference Between Arms of ≥2%] in TALAPRO-2Abbreviation: N=number of patients. |
|
| TALZENNA with Enzalutamide N=197 | Placebo with Enzalutamide N=199 |
Grades 1-4 % | Grade 3 % | Grade 4 % | Grades 1-4 % | Grade 3 % | Grade 4 % |
Fatigue† | 49 | 4 | 0 | 40 | 1 | 0 |
Nausea | 21 | 2 | 0 | 17 | 1 | 0.5 |
Decreased appetite | 20 | 1 | 0 | 14 | 1 | 1 |
Fractures‡ | 14 | 3 | 0 | 10 | 1.5 | 0 |
Dizziness§ | 13 | 1.5 | 0 | 9 | 1.5 | 0 |
Dysgeusia¶ | 10 | 0 | 0 | 4.5 | 0 | 0 |
Clinically relevant adverse reactions in <10% of patients who received TALZENNA with enzalutamide included abdominal pain (9%), vomiting (9%), alopecia (7%), dyspepsia (4%), venous thromboembolism (3%) and stomatitis (2%).
Table 8. Select Laboratory Abnormalities (≥10%) That Worsened from Baseline in Patients Who Received TALZENNA in TALAPRO-2Abbreviation: N=number of patients. |
|
Laboratory Abnormality | TALZENNA with Enzalutamide N=197* | Placebo with Enzalutamide N=199* |
Grades 1‑4 % | Grade 3 % | Grade 4 % | Grades 1‑4 % | Grade 3 % | Grade 4 % |
Hemoglobin decreased | 79 | 41 | 0 | 34 | 6 | 0 |
Neutrophils decreased | 60 | 18 | 1 | 18 | 0 | 1 |
Lymphocytes decreased | 58 | 13 | 0 | 36 | 7 | 0 |
Platelets decreased | 45 | 6 | 3 | 8 | 0.5 | 0 |
Calcium decreased | 25 | 0 | 1 | 11 | 0 | 1 |
Sodium decreased | 22 | 3 | 0 | 20 | 1.5 | 0 |
Phosphate decreased | 17 | 3 | 1 | 13 | 2 | 0 |
Magnesium decreased | 14 | 0 | 1 | 12 | 0 | 0.5 |
Bilirubin increased | 11 | 0.5 | 0 | 7 | 0 | 0 |
Potassium decreased | 11 | 0 | 1 | 7 | 1 | 0.5 |